Bone Quality Heterogeneity and Fragility Risk: Clinical Implications and Recent Advances

Abstract

Bone quality heterogeneity has emerged as a pivotal determinant of skeletal fragility, transcending traditional reliance on bone mineral density (BMD) for fracture risk assessment. This review evaluates the multifaceted nature of bone quality, encompassing microarchitecture, turnover, mineralization, and collagen cross-linking, and explores their interplay in fragility risk among diverse populations. Recent advances in imaging, biomarkers, and therapeutic strategies are discussed, with a focus on integrating bone quality assessment into clinical decision-making for fracture prevention.

Introduction

Osteoporotic fractures represent a significant cause of morbidity, mortality, and healthcare burden worldwide, particularly among the aging population. While BMD remains the cornerstone for diagnosing osteoporosis, accumulating evidence underscores the importance of bone quality an umbrella term encompassing structural and material properties in determining bone strength and fracture susceptibility. Understanding the heterogeneity of bone quality and its role in fragility risk is critical for clinicians seeking to optimize patient outcomes through personalized management strategies.

Epidemiology / Disease Burden

Globally, osteoporosis affects approximately 200 million individuals, with one in three women and one in five men over 50 years experiencing fragility fractures during their lifetime. Vertebral, hip, and wrist fractures account for the majority of osteoporosis-related events, leading to increased mortality, loss of independence, and substantial healthcare expenditures. Notably, up to 50% of individuals with fragility fractures have BMD values above the osteoporotic threshold, highlighting the limitations of BMD-centric risk stratification and the epidemiological relevance of bone quality heterogeneity in clinical practice.

Pathophysiology

Bone quality is determined by a constellation of factors beyond bone mass, including microarchitecture (trabecular and cortical structure), bone turnover rate, degree of mineralization, collagen properties, microdamage accumulation, and the presence of non-collagenous proteins. Heterogeneity in these components affects bone's mechanical competence. For instance, deterioration in trabecular connectivity or increased cortical porosity compromises bone integrity irrespective of BMD. Advanced glycation end-products (AGEs) in collagen, oxidative stress, and alterations in bone cell activity further modulate bone material quality, enhancing fragility risk even in individuals with normal or mildly reduced BMD.

Risk Factors

Traditional risk factors for compromised bone quality include advanced age, female sex, menopause, glucocorticoid therapy, chronic inflammatory diseases, diabetes mellitus, and chronic kidney disease. Lifestyle factors such as smoking, excessive alcohol consumption, physical inactivity, and poor nutrition also contribute to bone quality deterioration. Genetic predisposition influences both bone mass and quality, with polymorphisms affecting collagen synthesis, Wnt signaling, and osteoblast/osteoclast activity. Notably, bone quality heterogeneity is accentuated in secondary osteoporosis, where comorbidities and medications independently disrupt bone remodeling and microarchitecture.

Clinical Features

Patients with poor bone quality may present with fragility fractures after minimal trauma, commonly involving the spine, hip, or distal radius. Clinical features are often subtle until a fracture occurs, although vertebral fractures may manifest as back pain, height loss, or kyphosis. Unlike classical osteoporosis, some individuals with normal BMD experience fractures due to underlying deficits in bone microstructure or matrix composition, underscoring the clinical significance of bone quality assessment in at-risk populations.

Diagnosis

While dual-energy X-ray absorptiometry (DXA) remains the gold standard for measuring BMD, it does not capture aspects of bone quality. Advanced imaging modalities, including trabecular bone score (TBS), high-resolution peripheral quantitative computed tomography (HR-pQCT), and magnetic resonance imaging (MRI), provide insights into bone microarchitecture. Bone turnover markers (e.g., serum CTX, P1NP) and assays for collagen cross-links offer adjunctive information on bone remodeling dynamics. The integration of these tools with clinical risk assessment models, such as FRAX, enhances the identification of individuals at elevated fragility risk despite non-osteoporotic BMD values.

Treatment & Management

Management of bone fragility requires a comprehensive approach addressing both bone mass and quality. Anti-resorptive agents (bisphosphonates, denosumab) and anabolic therapies (teriparatide, abaloparatide, romosozumab) have demonstrated efficacy in reducing fracture risk by improving bone microarchitecture and material properties. Optimization of calcium and vitamin D status, fall prevention strategies, and management of underlying comorbidities are essential adjuncts. Individualized therapy selection, based on fracture history, risk profile, and potential for bone quality improvement, is recommended.

Recent Advances / Emerging Therapies

Recent advances in bone research have yielded novel insights into the molecular regulation of bone quality. Targeted therapies modulating sclerostin (romosozumab) and cathepsin K (odanacatib, in development) show promise in enhancing bone structure and strength. Emerging diagnostics, such as microindentation techniques and advanced imaging biomarkers, enable in vivo assessment of bone material properties. The integration of artificial intelligence and machine learning with imaging data offers potential for personalized fragility risk prediction based on bone quality heterogeneity.

Guideline Recommendations

International guidelines, including those from the International Osteoporosis Foundation (IOF) and American Association of Clinical Endocrinologists (AACE), recognize the importance of bone quality in fracture risk assessment. Recommendations emphasize the use of clinical risk factors, imaging adjuncts (TBS, HR-pQCT), and biochemical markers to complement BMD measurement. Treatment decisions should be individualized, taking into account not only BMD but also fracture history, age, comorbidities, and evidence of microarchitectural compromise. Ongoing research is expected to refine these recommendations as novel diagnostics and therapies become clinically available.

Conclusion

Bone quality heterogeneity represents a critical, yet underappreciated, determinant of skeletal fragility and fracture risk. Advances in diagnostic tools and therapeutics have improved our ability to assess and target bone quality deficits, offering hope for more effective fracture prevention strategies. Integration of bone quality assessment into routine clinical practice, guided by updated evidence-based recommendations, is essential for optimizing patient outcomes in the management of osteoporosis and related disorders.